Synapse - Michael Morris

Michael Morris

Morris michael

Groups

Solid Tumor Oncology Division
- Genitourinary Oncology Service
Department of Medicine

Research Focus

Medicine; Attending

1877

Recent additions – View all

PSMAfore: A phase 3 study to compare (177)Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer
Meeting Abstract

Sartor, A. O.; Morris, M. J.; Chi, K. N.; De Bono, J. S.; Shore, N. D.; Crosby, M.; Kreisl, T. N.; Fizazi, K.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)
Meeting Abstract

Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save
PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer
Meeting Abstract

Sartor, A. O.; Tagawa, S. T.; Saad, F.; De Bono, J. S.; Feng, F. Y.; Fizazi, K.; Sakharova, O. V.; Morris, M. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Co-authors at MSK

Types of Work

Publications

Journal of Clinical Oncology (185)
Journal of Nuclear Medicine (34)
Clinical Cancer Research (26)
Annals of Oncology (16)
Cancer (16)
Clinical Genitourinary Cancer (9)
Journal of Urology (8)
European Urology (7)
JAMA Oncology (7)
European Journal of Nuclear Medicine and Molecular Imaging (6)